Guo Xiaoxia, Jing Lele, Zhai Changlin, Shen Liang, Hu Huilin
Department of Cardiology, Affiliated Hospital of Jiaxing University, Jiaxing, China.
Clin Cardiol. 2025 Jan;48(1):e70076. doi: 10.1002/clc.70076.
Heart failure is extremely harmful to human health and social economics. The purpose of standardized heart failure management center (SHFMC) is to correct the non-standardization of heart failure treatment.
SHFMC has a positive impact on the management and prognosis of patients with chronic heart failure (CHF).
The SHFMC database of Jiaxing First Hospital was retrospectively analyzed. Two hundred sixty-three patients with CHF who were hospitalized in the cardiovascular medicine department of Jiaxing First Hospital in Zhejiang Province from January 2020 to December 2020 were identified as study subjects. The SHFMC opening day, July 1, 2020, was used as the dividing line around which the patients were divided into Group A (before the completion of SHFMC, n = 137) and Group B (after, n = 126). The baseline data, treatment standardization, long-term efficacy, 1-year all-cause mortality, and readmission rate of the two groups were compared.
The use of angiotensin receptor enkephalinase inhibitors (ARNIs), β-blockers (β-Bs), and sodium-glucose cotransport protein 2 inhibitors (SGLT2is) increased significantly, and the long-term outcome, readmission rate, and 1-year all-cause mortality of patients improved in group B.
The construction of SHFMC has been associated with consistent improvements in the standardization of CHF treatment, long-term patient outcomes, 1-year cumulative survival rates, and readmission rates.
心力衰竭对人类健康和社会经济危害极大。标准化心力衰竭管理中心(SHFMC)的目的是纠正心力衰竭治疗的不规范情况。
SHFMC对慢性心力衰竭(CHF)患者的管理和预后有积极影响。
对嘉兴市第一医院的SHFMC数据库进行回顾性分析。将2020年1月至2020年12月在浙江省嘉兴市第一医院心血管内科住院的263例CHF患者确定为研究对象。以SHFMC开业日2020年7月1日为分界线,将患者分为A组(SHFMC建成前,n = 137)和B组(建成后,n = 126)。比较两组的基线数据、治疗标准化程度、长期疗效、1年全因死亡率和再入院率。
B组血管紧张素受体脑啡肽酶抑制剂(ARNI)、β受体阻滞剂(β-B)和钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)的使用显著增加,患者的长期结局、再入院率和1年全因死亡率得到改善。
SHFMC的建设与CHF治疗标准化、患者长期结局、1年累积生存率和再入院率的持续改善相关。